Figure S5 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors As Modulators of Antiangiogenic Therapies

Figure S5: A) Levels of phosphorylated ERK following treatment of the MDST8 colorectal cell line, expressing R1032Q VEGFR2, with different kinase inhibitors in the presence. B) Proliferation assays of Colo320 cell lines, stably expressing WT and R1032Q VEGFR2, upon treatment with TKIs. The expression of the VEGFR2 R1032Q hot-spot mutant in Colo320 cell lines (WT to KRAS/NRAS/BRAF/PIK3CA and mutated to TP53 and APC) increased sensitivity to cabozantinib.